Evidence map›Paper›PMID 41727504›Full record

ArticleFrontiers in immunology2026

Comprehensive analysis of mitochondrial unfolded protein response related genes for prognosis and therapeutic response in pancreatic cancer.

Chengqing Li, Cuiling Lu, Zheng Ma, Ting Zhao, Mingming Xiao, Zhonglei Xu, Zhenxing Sun, Qihao Wu, Lei Wang, Liang Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chengqing Li *Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Cuiling Lu *Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Zheng Ma *Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Ting ZhaoPancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Mingming XiaoPancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Zhonglei XuPancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Zhenxing SunPancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Qihao WuPancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Lei WangDepartment of Pancreatic Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, China.
Liang ZhaoPancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pancreatic cancer (PC) is a highly aggressive malignancy of the digestive system, with an extremely poor prognosis. The mitochondrial unfolded protein response (UPR Methods: Gene expression data were obtained from TCGA, GEO, and CPTAC databases. Consensus clustering was performed based on MRGs, with subsequent evaluation of immune infiltration patterns across clusters. Prognostic MRGs were identified using three machine learning algorithms: LASSO regression, Random Survival Forest (RSF), and Extreme Gradient Boosting (XGBoost), combined with Cox regression analysis to establish a MRGs risk score (MRS). Quantitative real-time PCR (qRT-PCR) and western blotting were employed to validate potential mechanisms. Drug sensitivity profiling distinguished therapeutic responses between risk groups. Finally, we developed an MRS-based prognostic nomogram and validated it in multiple cohorts. Results: PC patients were stratified into two distinct UPR Conclusion: Our study systematically characterizes the prognostic and therapeutic implications of MRGs in PC, establishing a 3-gene MRS capable of reliably predicting OS in PC patients and exploring UPR

Indexed as

Biomarkers, TumorMitochondriaPancreatic NeoplasmsUnfolded Protein ResponseDrug Resistance, NeoplasmGene Expression ProfilingGene Expression Regulation, NeoplasticHumansNomogramsPrognosisBiomarkers, Tumordrug sensitivitymachine learningmitochondrial unfolded protein responsenomogrampancreatic cancerprognosis

Identifiers

PMID41727504
PMCPMC12916624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.